nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—Vandetanib—VEGFA—uterine cancer	0.0029	1	CrCbGaD
Bosutinib—STK24—Teniposide—Etoposide—uterine cancer	0.00104	0.112	CbGdCrCtD
Bosutinib—MAP4K4—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	0.000735	0.0797	CbGdCrCtD
Bosutinib—CASK—Teniposide—Etoposide—uterine cancer	0.000668	0.0724	CbGdCrCtD
Bosutinib—PLK2—Levonorgestrel—Progesterone—uterine cancer	0.000665	0.0721	CbGdCrCtD
Bosutinib—MAP4K4—Testosterone Propionate—Progesterone—uterine cancer	0.000641	0.0695	CbGdCrCtD
Bosutinib—WEE1—Daunorubicin—Epirubicin—uterine cancer	0.000606	0.0657	CbGdCrCtD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—uterine cancer	0.000561	0.0608	CbGdCrCtD
Bosutinib—Feeling abnormal—Progesterone—uterine cancer	0.000517	0.00216	CcSEcCtD
Bosutinib—Gastrointestinal pain—Progesterone—uterine cancer	0.000513	0.00214	CcSEcCtD
Bosutinib—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000507	0.00212	CcSEcCtD
Bosutinib—Pneumonia—Etoposide—uterine cancer	0.000506	0.00211	CcSEcCtD
Bosutinib—Ill-defined disorder—Dactinomycin—uterine cancer	0.000504	0.0021	CcSEcCtD
Bosutinib—Infestation—Etoposide—uterine cancer	0.000503	0.0021	CcSEcCtD
Bosutinib—Infestation NOS—Etoposide—uterine cancer	0.000503	0.0021	CcSEcCtD
Bosutinib—Anaemia—Dactinomycin—uterine cancer	0.000502	0.0021	CcSEcCtD
Bosutinib—Urticaria—Progesterone—uterine cancer	0.000498	0.00208	CcSEcCtD
Bosutinib—Body temperature increased—Progesterone—uterine cancer	0.000496	0.00207	CcSEcCtD
Bosutinib—Abdominal pain—Progesterone—uterine cancer	0.000496	0.00207	CcSEcCtD
Bosutinib—Hyperkalaemia—Epirubicin—uterine cancer	0.000495	0.00207	CcSEcCtD
Bosutinib—Renal failure—Etoposide—uterine cancer	0.000495	0.00207	CcSEcCtD
Bosutinib—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000494	0.00206	CcSEcCtD
Bosutinib—Blood bilirubin increased—Doxorubicin—uterine cancer	0.000493	0.00206	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000491	0.00205	CcSEcCtD
Bosutinib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00049	0.00205	CcSEcCtD
Bosutinib—Malaise—Dactinomycin—uterine cancer	0.00049	0.00205	CcSEcCtD
Bosutinib—Leukopenia—Dactinomycin—uterine cancer	0.000486	0.00203	CcSEcCtD
Bosutinib—Fluid retention—Epirubicin—uterine cancer	0.000479	0.002	CcSEcCtD
Bosutinib—Hepatobiliary disease—Etoposide—uterine cancer	0.000476	0.00199	CcSEcCtD
Bosutinib—Agranulocytosis—Etoposide—uterine cancer	0.00047	0.00196	CcSEcCtD
Bosutinib—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000468	0.00196	CcSEcCtD
Bosutinib—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000465	0.00194	CcSEcCtD
Bosutinib—Myalgia—Dactinomycin—uterine cancer	0.000463	0.00193	CcSEcCtD
Bosutinib—Hyperkalaemia—Doxorubicin—uterine cancer	0.000458	0.00191	CcSEcCtD
Bosutinib—Rash maculo-papular—Epirubicin—uterine cancer	0.000458	0.00191	CcSEcCtD
Bosutinib—Discomfort—Dactinomycin—uterine cancer	0.000457	0.00191	CcSEcCtD
Bosutinib—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000452	0.00189	CcSEcCtD
Bosutinib—Asthenia—Progesterone—uterine cancer	0.00045	0.00188	CcSEcCtD
Bosutinib—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000449	0.00188	CcSEcCtD
Bosutinib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000449	0.00188	CcSEcCtD
Bosutinib—Urinary tract disorder—Etoposide—uterine cancer	0.000446	0.00186	CcSEcCtD
Bosutinib—Pruritus—Progesterone—uterine cancer	0.000444	0.00185	CcSEcCtD
Bosutinib—Oedema—Dactinomycin—uterine cancer	0.000443	0.00185	CcSEcCtD
Bosutinib—Fluid retention—Doxorubicin—uterine cancer	0.000443	0.00185	CcSEcCtD
Bosutinib—Urethral disorder—Etoposide—uterine cancer	0.000443	0.00185	CcSEcCtD
Bosutinib—Infection—Dactinomycin—uterine cancer	0.00044	0.00184	CcSEcCtD
Bosutinib—Thrombocytopenia—Dactinomycin—uterine cancer	0.000434	0.00181	CcSEcCtD
Bosutinib—ERBB3—Podofilox—Etoposide—uterine cancer	0.00043	0.0466	CbGdCrCtD
Bosutinib—Diarrhoea—Progesterone—uterine cancer	0.000429	0.00179	CcSEcCtD
Bosutinib—Erythema multiforme—Etoposide—uterine cancer	0.000427	0.00178	CcSEcCtD
Bosutinib—Rash maculo-papular—Doxorubicin—uterine cancer	0.000424	0.00177	CcSEcCtD
Bosutinib—Cardiac disorder—Etoposide—uterine cancer	0.000419	0.00175	CcSEcCtD
Bosutinib—Hepatic function abnormal—Epirubicin—uterine cancer	0.000419	0.00175	CcSEcCtD
Bosutinib—Dizziness—Progesterone—uterine cancer	0.000415	0.00173	CcSEcCtD
Bosutinib—Immune system disorder—Etoposide—uterine cancer	0.000408	0.0017	CcSEcCtD
Bosutinib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000408	0.0017	CcSEcCtD
Bosutinib—Mediastinal disorder—Etoposide—uterine cancer	0.000407	0.0017	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000404	0.00169	CcSEcCtD
Bosutinib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000402	0.00168	CcSEcCtD
Bosutinib—Vomiting—Progesterone—uterine cancer	0.000399	0.00167	CcSEcCtD
Bosutinib—Renal failure acute—Epirubicin—uterine cancer	0.000396	0.00166	CcSEcCtD
Bosutinib—Rash—Progesterone—uterine cancer	0.000396	0.00165	CcSEcCtD
Bosutinib—Dermatitis—Progesterone—uterine cancer	0.000395	0.00165	CcSEcCtD
Bosutinib—Headache—Progesterone—uterine cancer	0.000393	0.00164	CcSEcCtD
Bosutinib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000389	0.00162	CcSEcCtD
Bosutinib—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000387	0.00162	CcSEcCtD
Bosutinib—Decreased appetite—Dactinomycin—uterine cancer	0.000385	0.00161	CcSEcCtD
Bosutinib—Dysgeusia—Etoposide—uterine cancer	0.000385	0.00161	CcSEcCtD
Bosutinib—Renal impairment—Epirubicin—uterine cancer	0.000385	0.00161	CcSEcCtD
Bosutinib—Fatigue—Dactinomycin—uterine cancer	0.000382	0.0016	CcSEcCtD
Bosutinib—Back pain—Etoposide—uterine cancer	0.00038	0.00159	CcSEcCtD
Bosutinib—Pain—Dactinomycin—uterine cancer	0.000379	0.00158	CcSEcCtD
Bosutinib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000376	0.00157	CcSEcCtD
Bosutinib—STK10—uterine cervix—uterine cancer	0.000376	0.00113	CbGeAlD
Bosutinib—LCK—uterus—uterine cancer	0.000376	0.00113	CbGeAlD
Bosutinib—STK35—female gonad—uterine cancer	0.000376	0.00113	CbGeAlD
Bosutinib—MAP2K1—female gonad—uterine cancer	0.000376	0.00113	CbGeAlD
Bosutinib—EPHB4—mammalian vulva—uterine cancer	0.000375	0.00113	CbGeAlD
Bosutinib—FES—lymph node—uterine cancer	0.000375	0.00113	CbGeAlD
Bosutinib—VRK2—lymph node—uterine cancer	0.000375	0.00113	CbGeAlD
Bosutinib—TAOK3—uterine cervix—uterine cancer	0.000374	0.00113	CbGeAlD
Bosutinib—AXL—uterus—uterine cancer	0.000374	0.00112	CbGeAlD
Bosutinib—PDGFRB—myometrium—uterine cancer	0.000373	0.00112	CbGeAlD
Bosutinib—STK35—vagina—uterine cancer	0.000373	0.00112	CbGeAlD
Bosutinib—CSK—female gonad—uterine cancer	0.000373	0.00112	CbGeAlD
Bosutinib—Nausea—Progesterone—uterine cancer	0.000373	0.00156	CcSEcCtD
Bosutinib—SIK1—female reproductive system—uterine cancer	0.000372	0.00112	CbGeAlD
Bosutinib—MAP4K5—endometrium—uterine cancer	0.000371	0.00112	CbGeAlD
Bosutinib—MAP3K3—endometrium—uterine cancer	0.000371	0.00112	CbGeAlD
Bosutinib—CSK—vagina—uterine cancer	0.000371	0.00111	CbGeAlD
Bosutinib—CSNK1A1—female gonad—uterine cancer	0.000371	0.00111	CbGeAlD
Bosutinib—YES1—smooth muscle tissue—uterine cancer	0.000369	0.00111	CbGeAlD
Bosutinib—CSNK1A1—vagina—uterine cancer	0.000368	0.00111	CbGeAlD
Bosutinib—EPHA2—mammalian vulva—uterine cancer	0.000368	0.00111	CbGeAlD
Bosutinib—HCK—female gonad—uterine cancer	0.000368	0.00111	CbGeAlD
Bosutinib—CLK1—female gonad—uterine cancer	0.000368	0.00111	CbGeAlD
Bosutinib—SRC—epithelium—uterine cancer	0.000368	0.00111	CbGeAlD
Bosutinib—EPHA4—female reproductive system—uterine cancer	0.000368	0.00111	CbGeAlD
Bosutinib—FYN—mammalian vulva—uterine cancer	0.000368	0.0011	CbGeAlD
Bosutinib—SYK—lymph node—uterine cancer	0.000367	0.0011	CbGeAlD
Bosutinib—TNIK—lymph node—uterine cancer	0.000367	0.0011	CbGeAlD
Bosutinib—Renal failure acute—Doxorubicin—uterine cancer	0.000367	0.00153	CcSEcCtD
Bosutinib—HCK—vagina—uterine cancer	0.000366	0.0011	CbGeAlD
Bosutinib—CLK1—vagina—uterine cancer	0.000366	0.0011	CbGeAlD
Bosutinib—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000366	0.00153	CcSEcCtD
Bosutinib—ABL2—female gonad—uterine cancer	0.000366	0.0011	CbGeAlD
Bosutinib—Feeling abnormal—Dactinomycin—uterine cancer	0.000365	0.00153	CcSEcCtD
Bosutinib—SRC—uterine cervix—uterine cancer	0.000365	0.0011	CbGeAlD
Bosutinib—Ill-defined disorder—Etoposide—uterine cancer	0.000365	0.00152	CcSEcCtD
Bosutinib—ERBB3—female reproductive system—uterine cancer	0.000364	0.00109	CbGeAlD
Bosutinib—CDK2—lymph node—uterine cancer	0.000364	0.00109	CbGeAlD
Bosutinib—ABL2—vagina—uterine cancer	0.000364	0.00109	CbGeAlD
Bosutinib—Anaemia—Etoposide—uterine cancer	0.000363	0.00152	CcSEcCtD
Bosutinib—MAP2K2—female reproductive system—uterine cancer	0.000363	0.00109	CbGeAlD
Bosutinib—ULK3—female reproductive system—uterine cancer	0.000363	0.00109	CbGeAlD
Bosutinib—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000363	0.00151	CcSEcCtD
Bosutinib—BMP2K—female gonad—uterine cancer	0.000361	0.00109	CbGeAlD
Bosutinib—CAMK2G—female gonad—uterine cancer	0.000361	0.00109	CbGeAlD
Bosutinib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000361	0.00151	CcSEcCtD
Bosutinib—YES1—decidua—uterine cancer	0.000361	0.00109	CbGeAlD
Bosutinib—MAP3K2—female reproductive system—uterine cancer	0.000361	0.00108	CbGeAlD
Bosutinib—STK26—lymph node—uterine cancer	0.000361	0.00108	CbGeAlD
Bosutinib—SLK—uterus—uterine cancer	0.00036	0.00108	CbGeAlD
Bosutinib—MAP3K3—mammalian vulva—uterine cancer	0.000359	0.00108	CbGeAlD
Bosutinib—MAP4K5—mammalian vulva—uterine cancer	0.000359	0.00108	CbGeAlD
Bosutinib—BMP2K—vagina—uterine cancer	0.000359	0.00108	CbGeAlD
Bosutinib—CAMK2G—vagina—uterine cancer	0.000359	0.00108	CbGeAlD
Bosutinib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000358	0.0015	CcSEcCtD
Bosutinib—LRRK2—female gonad—uterine cancer	0.000358	0.00108	CbGeAlD
Bosutinib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000358	0.0015	CcSEcCtD
Bosutinib—STK10—decidua—uterine cancer	0.000358	0.00108	CbGeAlD
Bosutinib—EPHB4—uterus—uterine cancer	0.000358	0.00107	CbGeAlD
Bosutinib—EGFR—female gonad—uterine cancer	0.000357	0.00107	CbGeAlD
Bosutinib—TAOK3—decidua—uterine cancer	0.000357	0.00107	CbGeAlD
Bosutinib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000356	0.00149	CcSEcCtD
Bosutinib—LRRK2—vagina—uterine cancer	0.000356	0.00107	CbGeAlD
Bosutinib—Renal impairment—Doxorubicin—uterine cancer	0.000356	0.00149	CcSEcCtD
Bosutinib—YES1—renal system—uterine cancer	0.000355	0.00107	CbGeAlD
Bosutinib—Malaise—Etoposide—uterine cancer	0.000355	0.00148	CcSEcCtD
Bosutinib—SRC—smooth muscle tissue—uterine cancer	0.000355	0.00107	CbGeAlD
Bosutinib—Face oedema—Epirubicin—uterine cancer	0.000353	0.00148	CcSEcCtD
Bosutinib—PTK2—female reproductive system—uterine cancer	0.000353	0.00106	CbGeAlD
Bosutinib—TBK1—female reproductive system—uterine cancer	0.000353	0.00106	CbGeAlD
Bosutinib—Leukopenia—Etoposide—uterine cancer	0.000352	0.00147	CcSEcCtD
Bosutinib—STK10—renal system—uterine cancer	0.000352	0.00106	CbGeAlD
Bosutinib—Body temperature increased—Dactinomycin—uterine cancer	0.000351	0.00146	CcSEcCtD
Bosutinib—Abdominal pain—Dactinomycin—uterine cancer	0.000351	0.00146	CcSEcCtD
Bosutinib—TAOK3—renal system—uterine cancer	0.00035	0.00105	CbGeAlD
Bosutinib—FYN—uterus—uterine cancer	0.00035	0.00105	CbGeAlD
Bosutinib—PTK2B—female gonad—uterine cancer	0.000349	0.00105	CbGeAlD
Bosutinib—CHEK2—lymph node—uterine cancer	0.000348	0.00105	CbGeAlD
Bosutinib—SRC—decidua—uterine cancer	0.000348	0.00104	CbGeAlD
Bosutinib—PTK2B—vagina—uterine cancer	0.000347	0.00104	CbGeAlD
Bosutinib—IRAK1—female reproductive system—uterine cancer	0.000346	0.00104	CbGeAlD
Bosutinib—DMPK—lymph node—uterine cancer	0.000345	0.00104	CbGeAlD
Bosutinib—WEE1—lymph node—uterine cancer	0.000345	0.00104	CbGeAlD
Bosutinib—CSNK1E—female gonad—uterine cancer	0.000343	0.00103	CbGeAlD
Bosutinib—Cough—Etoposide—uterine cancer	0.000343	0.00143	CcSEcCtD
Bosutinib—YES1—endometrium—uterine cancer	0.000343	0.00103	CbGeAlD
Bosutinib—Blood creatinine increased—Epirubicin—uterine cancer	0.000343	0.00143	CcSEcCtD
Bosutinib—MAP4K5—uterus—uterine cancer	0.000342	0.00103	CbGeAlD
Bosutinib—CSNK1E—vagina—uterine cancer	0.000341	0.00103	CbGeAlD
Bosutinib—SRC—renal system—uterine cancer	0.000341	0.00103	CbGeAlD
Bosutinib—Dehydration—Epirubicin—uterine cancer	0.00034	0.00142	CcSEcCtD
Bosutinib—RPS6KB1—female reproductive system—uterine cancer	0.00034	0.00102	CbGeAlD
Bosutinib—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000339	0.00141	CcSEcCtD
Bosutinib—TAOK3—endometrium—uterine cancer	0.000339	0.00102	CbGeAlD
Bosutinib—SIK1—female gonad—uterine cancer	0.000338	0.00102	CbGeAlD
Bosutinib—IRAK4—female gonad—uterine cancer	0.000338	0.00102	CbGeAlD
Bosutinib—FGR—female reproductive system—uterine cancer	0.000338	0.00101	CbGeAlD
Bosutinib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000338	0.00141	CcSEcCtD
Bosutinib—AXL—female reproductive system—uterine cancer	0.000336	0.00101	CbGeAlD
Bosutinib—IRAK4—vagina—uterine cancer	0.000336	0.00101	CbGeAlD
Bosutinib—MAP2K5—uterine cervix—uterine cancer	0.000336	0.00101	CbGeAlD
Bosutinib—Chest pain—Etoposide—uterine cancer	0.000335	0.0014	CcSEcCtD
Bosutinib—EPHA4—female gonad—uterine cancer	0.000335	0.00101	CbGeAlD
Bosutinib—Abdominal pain upper—Epirubicin—uterine cancer	0.000334	0.0014	CcSEcCtD
Bosutinib—ABL1—myometrium—uterine cancer	0.000333	0.001	CbGeAlD
Bosutinib—EPHA4—vagina—uterine cancer	0.000333	0.001	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000332	0.00139	CcSEcCtD
Bosutinib—YES1—mammalian vulva—uterine cancer	0.000332	0.000997	CbGeAlD
Bosutinib—ERBB3—female gonad—uterine cancer	0.000331	0.000996	CbGeAlD
Bosutinib—Discomfort—Etoposide—uterine cancer	0.000331	0.00138	CcSEcCtD
Bosutinib—ULK3—female gonad—uterine cancer	0.000331	0.000993	CbGeAlD
Bosutinib—MAP2K2—female gonad—uterine cancer	0.000331	0.000993	CbGeAlD
Bosutinib—STK25—lymph node—uterine cancer	0.00033	0.000991	CbGeAlD
Bosutinib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.00033	0.00138	CcSEcCtD
Bosutinib—STK10—mammalian vulva—uterine cancer	0.000329	0.000988	CbGeAlD
Bosutinib—ULK3—vagina—uterine cancer	0.000329	0.000987	CbGeAlD
Bosutinib—MAP3K2—female gonad—uterine cancer	0.000328	0.000986	CbGeAlD
Bosutinib—TAOK3—mammalian vulva—uterine cancer	0.000328	0.000984	CbGeAlD
Bosutinib—CSF1R—uterine cervix—uterine cancer	0.000328	0.000984	CbGeAlD
Bosutinib—EPHA3—lymph node—uterine cancer	0.000327	0.000984	CbGeAlD
Bosutinib—Nasopharyngitis—Epirubicin—uterine cancer	0.000327	0.00137	CcSEcCtD
Bosutinib—Face oedema—Doxorubicin—uterine cancer	0.000327	0.00137	CcSEcCtD
Bosutinib—MAP3K7—female gonad—uterine cancer	0.000325	0.000977	CbGeAlD
Bosutinib—Gastritis—Epirubicin—uterine cancer	0.000324	0.00135	CcSEcCtD
Bosutinib—MAP3K7—vagina—uterine cancer	0.000323	0.000971	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000323	0.00135	CcSEcCtD
Bosutinib—EPHB4—female reproductive system—uterine cancer	0.000322	0.000966	CbGeAlD
Bosutinib—PTK2—female gonad—uterine cancer	0.000321	0.000966	CbGeAlD
Bosutinib—TBK1—female gonad—uterine cancer	0.000321	0.000966	CbGeAlD
Bosutinib—Anaphylactic shock—Etoposide—uterine cancer	0.000321	0.00134	CcSEcCtD
Bosutinib—PLK2—lymph node—uterine cancer	0.000321	0.000964	CbGeAlD
Bosutinib—MAP2K5—decidua—uterine cancer	0.00032	0.000961	CbGeAlD
Bosutinib—TBK1—vagina—uterine cancer	0.000319	0.00096	CbGeAlD
Bosutinib—PTK2—vagina—uterine cancer	0.000319	0.00096	CbGeAlD
Bosutinib—Infection—Etoposide—uterine cancer	0.000319	0.00133	CcSEcCtD
Bosutinib—SIK3—lymph node—uterine cancer	0.000319	0.000957	CbGeAlD
Bosutinib—CSF1R—smooth muscle tissue—uterine cancer	0.000318	0.000957	CbGeAlD
Bosutinib—Asthenia—Dactinomycin—uterine cancer	0.000318	0.00133	CcSEcCtD
Bosutinib—Blood creatinine increased—Doxorubicin—uterine cancer	0.000317	0.00132	CcSEcCtD
Bosutinib—Influenza—Epirubicin—uterine cancer	0.000316	0.00132	CcSEcCtD
Bosutinib—YES1—uterus—uterine cancer	0.000316	0.00095	CbGeAlD
Bosutinib—EPHA2—female reproductive system—uterine cancer	0.000315	0.000948	CbGeAlD
Bosutinib—IRAK1—female gonad—uterine cancer	0.000315	0.000947	CbGeAlD
Bosutinib—Dehydration—Doxorubicin—uterine cancer	0.000315	0.00132	CcSEcCtD
Bosutinib—FYN—female reproductive system—uterine cancer	0.000315	0.000946	CbGeAlD
Bosutinib—Thrombocytopenia—Etoposide—uterine cancer	0.000314	0.00131	CcSEcCtD
Bosutinib—STK10—uterus—uterine cancer	0.000313	0.000941	CbGeAlD
Bosutinib—CSF1R—decidua—uterine cancer	0.000312	0.000938	CbGeAlD
Bosutinib—TAOK3—uterus—uterine cancer	0.000312	0.000938	CbGeAlD
Bosutinib—Skin disorder—Etoposide—uterine cancer	0.000312	0.0013	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—uterine cancer	0.000309	0.00129	CcSEcCtD
Bosutinib—RPS6KB1—female gonad—uterine cancer	0.000309	0.000929	CbGeAlD
Bosutinib—MAP3K3—female reproductive system—uterine cancer	0.000308	0.000925	CbGeAlD
Bosutinib—MAP4K5—female reproductive system—uterine cancer	0.000308	0.000925	CbGeAlD
Bosutinib—RPS6KB1—vagina—uterine cancer	0.000307	0.000924	CbGeAlD
Bosutinib—LCK—female gonad—uterine cancer	0.000307	0.000924	CbGeAlD
Bosutinib—FGR—female gonad—uterine cancer	0.000307	0.000924	CbGeAlD
Bosutinib—STK4—lymph node—uterine cancer	0.000307	0.000921	CbGeAlD
Bosutinib—PKMYT1—Danazol—Progesterone—uterine cancer	0.000306	0.0332	CbGdCrCtD
Bosutinib—AXL—female gonad—uterine cancer	0.000306	0.00092	CbGeAlD
Bosutinib—FGR—vagina—uterine cancer	0.000305	0.000918	CbGeAlD
Bosutinib—LCK—vagina—uterine cancer	0.000305	0.000918	CbGeAlD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000305	0.00127	CcSEcCtD
Bosutinib—AXL—vagina—uterine cancer	0.000304	0.000914	CbGeAlD
Bosutinib—Bronchitis—Epirubicin—uterine cancer	0.000304	0.00127	CcSEcCtD
Bosutinib—MAP2K5—endometrium—uterine cancer	0.000304	0.000912	CbGeAlD
Bosutinib—Diarrhoea—Dactinomycin—uterine cancer	0.000303	0.00127	CcSEcCtD
Bosutinib—CAMK1D—lymph node—uterine cancer	0.000303	0.00091	CbGeAlD
Bosutinib—Nasopharyngitis—Doxorubicin—uterine cancer	0.000303	0.00126	CcSEcCtD
Bosutinib—Pancytopenia—Epirubicin—uterine cancer	0.0003	0.00125	CcSEcCtD
Bosutinib—Gastritis—Doxorubicin—uterine cancer	0.0003	0.00125	CcSEcCtD
Bosutinib—STK24—lymph node—uterine cancer	0.000299	0.0009	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000299	0.00125	CcSEcCtD
Bosutinib—CSF1R—endometrium—uterine cancer	0.000296	0.00089	CbGeAlD
Bosutinib—Neutropenia—Epirubicin—uterine cancer	0.000296	0.00124	CcSEcCtD
Bosutinib—SLK—female gonad—uterine cancer	0.000295	0.000885	CbGeAlD
Bosutinib—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000294	0.00123	CcSEcCtD
Bosutinib—MAP2K5—mammalian vulva—uterine cancer	0.000294	0.000882	CbGeAlD
Bosutinib—PDGFRB—epithelium—uterine cancer	0.000293	0.00088	CbGeAlD
Bosutinib—SLK—vagina—uterine cancer	0.000293	0.00088	CbGeAlD
Bosutinib—Influenza—Doxorubicin—uterine cancer	0.000293	0.00122	CcSEcCtD
Bosutinib—EPHB4—female gonad—uterine cancer	0.000293	0.000879	CbGeAlD
Bosutinib—CSNK1E—Danazol—Progesterone—uterine cancer	0.000292	0.0317	CbGdCrCtD
Bosutinib—EPHB4—vagina—uterine cancer	0.000291	0.000874	CbGeAlD
Bosutinib—CHEK2—Teniposide—Etoposide—uterine cancer	0.000291	0.0315	CbGdCrCtD
Bosutinib—CHEK2—Podofilox—Etoposide—uterine cancer	0.000291	0.0315	CbGdCrCtD
Bosutinib—PDGFRB—uterine cervix—uterine cancer	0.000291	0.000873	CbGeAlD
Bosutinib—FER—lymph node—uterine cancer	0.00029	0.000871	CbGeAlD
Bosutinib—ALK—lymph node—uterine cancer	0.00029	0.000871	CbGeAlD
Bosutinib—EPHA2—female gonad—uterine cancer	0.000287	0.000862	CbGeAlD
Bosutinib—CSF1R—mammalian vulva—uterine cancer	0.000287	0.000861	CbGeAlD
Bosutinib—FYN—female gonad—uterine cancer	0.000287	0.000861	CbGeAlD
Bosutinib—Dyspnoea—Etoposide—uterine cancer	0.000286	0.00119	CcSEcCtD
Bosutinib—EPHA2—vagina—uterine cancer	0.000285	0.000857	CbGeAlD
Bosutinib—FYN—vagina—uterine cancer	0.000285	0.000856	CbGeAlD
Bosutinib—YES1—female reproductive system—uterine cancer	0.000284	0.000854	CbGeAlD
Bosutinib—MAP4K1—lymph node—uterine cancer	0.000284	0.000853	CbGeAlD
Bosutinib—Pneumonia—Epirubicin—uterine cancer	0.000284	0.00118	CcSEcCtD
Bosutinib—BTK—lymph node—uterine cancer	0.000283	0.000849	CbGeAlD
Bosutinib—PDGFRB—smooth muscle tissue—uterine cancer	0.000282	0.000848	CbGeAlD
Bosutinib—Infestation NOS—Epirubicin—uterine cancer	0.000282	0.00118	CcSEcCtD
Bosutinib—Infestation—Epirubicin—uterine cancer	0.000282	0.00118	CcSEcCtD
Bosutinib—Vomiting—Dactinomycin—uterine cancer	0.000282	0.00118	CcSEcCtD
Bosutinib—STK10—female reproductive system—uterine cancer	0.000282	0.000846	CbGeAlD
Bosutinib—Bronchitis—Doxorubicin—uterine cancer	0.000281	0.00118	CcSEcCtD
Bosutinib—TAOK3—female reproductive system—uterine cancer	0.000281	0.000843	CbGeAlD
Bosutinib—MAP4K5—female gonad—uterine cancer	0.00028	0.000841	CbGeAlD
Bosutinib—MAP3K3—female gonad—uterine cancer	0.00028	0.000841	CbGeAlD
Bosutinib—Rash—Dactinomycin—uterine cancer	0.00028	0.00117	CcSEcCtD
Bosutinib—Decreased appetite—Etoposide—uterine cancer	0.000279	0.00116	CcSEcCtD
Bosutinib—TNK2—lymph node—uterine cancer	0.000278	0.000837	CbGeAlD
Bosutinib—MAP4K5—vagina—uterine cancer	0.000278	0.000836	CbGeAlD
Bosutinib—MAP3K3—vagina—uterine cancer	0.000278	0.000836	CbGeAlD
Bosutinib—Pancytopenia—Doxorubicin—uterine cancer	0.000278	0.00116	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—uterine cancer	0.000277	0.00116	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000277	0.00116	CcSEcCtD
Bosutinib—PDGFRB—decidua—uterine cancer	0.000277	0.000832	CbGeAlD
Bosutinib—Fatigue—Etoposide—uterine cancer	0.000277	0.00116	CcSEcCtD
Bosutinib—MAP4K2—lymph node—uterine cancer	0.000275	0.000825	CbGeAlD
Bosutinib—Pain—Etoposide—uterine cancer	0.000274	0.00115	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—uterine cancer	0.000274	0.00114	CcSEcCtD
Bosutinib—SRC—female reproductive system—uterine cancer	0.000273	0.000821	CbGeAlD
Bosutinib—CSF1R—uterus—uterine cancer	0.000273	0.00082	CbGeAlD
Bosutinib—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000272	0.00114	CcSEcCtD
Bosutinib—PDGFRB—renal system—uterine cancer	0.000272	0.000817	CbGeAlD
Bosutinib—STK3—lymph node—uterine cancer	0.000271	0.000814	CbGeAlD
Bosutinib—Hepatobiliary disease—Epirubicin—uterine cancer	0.000267	0.00111	CcSEcCtD
Bosutinib—Feeling abnormal—Etoposide—uterine cancer	0.000264	0.0011	CcSEcCtD
Bosutinib—Nausea—Dactinomycin—uterine cancer	0.000263	0.0011	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—uterine cancer	0.000263	0.0011	CcSEcCtD
Bosutinib—PDGFRB—endometrium—uterine cancer	0.000263	0.00079	CbGeAlD
Bosutinib—Pneumonia—Doxorubicin—uterine cancer	0.000262	0.0011	CcSEcCtD
Bosutinib—Gastrointestinal pain—Etoposide—uterine cancer	0.000262	0.0011	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—uterine cancer	0.000261	0.00109	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—uterine cancer	0.000261	0.00109	CcSEcCtD
Bosutinib—BMPR2—lymph node—uterine cancer	0.00026	0.00078	CbGeAlD
Bosutinib—ABL1—uterine cervix—uterine cancer	0.000259	0.000778	CbGeAlD
Bosutinib—YES1—female gonad—uterine cancer	0.000259	0.000777	CbGeAlD
Bosutinib—EPHB3—lymph node—uterine cancer	0.000258	0.000774	CbGeAlD
Bosutinib—STK36—lymph node—uterine cancer	0.000258	0.000774	CbGeAlD
Bosutinib—YES1—vagina—uterine cancer	0.000257	0.000772	CbGeAlD
Bosutinib—Renal failure—Doxorubicin—uterine cancer	0.000257	0.00107	CcSEcCtD
Bosutinib—STK10—female gonad—uterine cancer	0.000256	0.00077	CbGeAlD
Bosutinib—TAOK3—female gonad—uterine cancer	0.000255	0.000767	CbGeAlD
Bosutinib—Urticaria—Etoposide—uterine cancer	0.000255	0.00106	CcSEcCtD
Bosutinib—STK10—vagina—uterine cancer	0.000255	0.000765	CbGeAlD
Bosutinib—MERTK—lymph node—uterine cancer	0.000255	0.000765	CbGeAlD
Bosutinib—PDGFRB—mammalian vulva—uterine cancer	0.000254	0.000764	CbGeAlD
Bosutinib—TAOK3—vagina—uterine cancer	0.000254	0.000762	CbGeAlD
Bosutinib—Abdominal pain—Etoposide—uterine cancer	0.000254	0.00106	CcSEcCtD
Bosutinib—Body temperature increased—Etoposide—uterine cancer	0.000254	0.00106	CcSEcCtD
Bosutinib—Hepatitis—Epirubicin—uterine cancer	0.000253	0.00106	CcSEcCtD
Bosutinib—ABL1—smooth muscle tissue—uterine cancer	0.000252	0.000756	CbGeAlD
Bosutinib—MAP2K5—female reproductive system—uterine cancer	0.000251	0.000756	CbGeAlD
Bosutinib—Urinary tract disorder—Epirubicin—uterine cancer	0.00025	0.00104	CcSEcCtD
Bosutinib—MAP4K4—lymph node—uterine cancer	0.00025	0.000751	CbGeAlD
Bosutinib—Oedema peripheral—Epirubicin—uterine cancer	0.000249	0.00104	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—uterine cancer	0.000249	0.00104	CcSEcCtD
Bosutinib—SRC—female gonad—uterine cancer	0.000249	0.000747	CbGeAlD
Bosutinib—Urethral disorder—Epirubicin—uterine cancer	0.000248	0.00104	CcSEcCtD
Bosutinib—BCR—lymph node—uterine cancer	0.000248	0.000746	CbGeAlD
Bosutinib—NUAK2—lymph node—uterine cancer	0.000248	0.000746	CbGeAlD
Bosutinib—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000247	0.00103	CcSEcCtD
Bosutinib—ABL1—decidua—uterine cancer	0.000247	0.000741	CbGeAlD
Bosutinib—MAP3K12—lymph node—uterine cancer	0.000246	0.00074	CbGeAlD
Bosutinib—CSF1R—female reproductive system—uterine cancer	0.000245	0.000737	CbGeAlD
Bosutinib—Agranulocytosis—Doxorubicin—uterine cancer	0.000244	0.00102	CcSEcCtD
Bosutinib—ABL1—renal system—uterine cancer	0.000242	0.000728	CbGeAlD
Bosutinib—PDGFRB—uterus—uterine cancer	0.000242	0.000728	CbGeAlD
Bosutinib—MAP2K1—lymph node—uterine cancer	0.000241	0.000725	CbGeAlD
Bosutinib—STK35—lymph node—uterine cancer	0.000241	0.000725	CbGeAlD
Bosutinib—CSK—lymph node—uterine cancer	0.00024	0.000721	CbGeAlD
Bosutinib—Erythema multiforme—Epirubicin—uterine cancer	0.000239	0.001	CcSEcCtD
Bosutinib—CSNK1A1—lymph node—uterine cancer	0.000238	0.000716	CbGeAlD
Bosutinib—HCK—lymph node—uterine cancer	0.000237	0.000711	CbGeAlD
Bosutinib—CLK1—lymph node—uterine cancer	0.000237	0.000711	CbGeAlD
Bosutinib—Tinnitus—Epirubicin—uterine cancer	0.000236	0.000986	CcSEcCtD
Bosutinib—ABL2—lymph node—uterine cancer	0.000235	0.000707	CbGeAlD
Bosutinib—Cardiac disorder—Epirubicin—uterine cancer	0.000235	0.000981	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—uterine cancer	0.000234	0.000978	CcSEcCtD
Bosutinib—ABL1—endometrium—uterine cancer	0.000234	0.000704	CbGeAlD
Bosutinib—BMP2K—lymph node—uterine cancer	0.000232	0.000698	CbGeAlD
Bosutinib—CAMK2G—lymph node—uterine cancer	0.000232	0.000698	CbGeAlD
Bosutinib—Urinary tract disorder—Doxorubicin—uterine cancer	0.000231	0.000966	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—uterine cancer	0.000231	0.000964	CcSEcCtD
Bosutinib—LRRK2—lymph node—uterine cancer	0.00023	0.000692	CbGeAlD
Bosutinib—Asthenia—Etoposide—uterine cancer	0.00023	0.000961	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—uterine cancer	0.00023	0.000961	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—uterine cancer	0.00023	0.000959	CcSEcCtD
Bosutinib—EGFR—lymph node—uterine cancer	0.00023	0.00069	CbGeAlD
Bosutinib—MAP2K5—female gonad—uterine cancer	0.000229	0.000688	CbGeAlD
Bosutinib—Immune system disorder—Epirubicin—uterine cancer	0.000229	0.000955	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—uterine cancer	0.000228	0.000953	CcSEcCtD
Bosutinib—MAP2K5—vagina—uterine cancer	0.000227	0.000683	CbGeAlD
Bosutinib—Pruritus—Etoposide—uterine cancer	0.000227	0.000948	CcSEcCtD
Bosutinib—ABL1—mammalian vulva—uterine cancer	0.000227	0.000681	CbGeAlD
Bosutinib—PTK2B—lymph node—uterine cancer	0.000224	0.000674	CbGeAlD
Bosutinib—CSF1R—female gonad—uterine cancer	0.000223	0.000671	CbGeAlD
Bosutinib—CSF1R—vagina—uterine cancer	0.000222	0.000667	CbGeAlD
Bosutinib—Erythema multiforme—Doxorubicin—uterine cancer	0.000222	0.000925	CcSEcCtD
Bosutinib—CSNK1E—lymph node—uterine cancer	0.000221	0.000663	CbGeAlD
Bosutinib—Malnutrition—Epirubicin—uterine cancer	0.00022	0.00092	CcSEcCtD
Bosutinib—Diarrhoea—Etoposide—uterine cancer	0.00022	0.000917	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—uterine cancer	0.000218	0.000912	CcSEcCtD
Bosutinib—PDGFRB—female reproductive system—uterine cancer	0.000218	0.000654	CbGeAlD
Bosutinib—Cardiac disorder—Doxorubicin—uterine cancer	0.000217	0.000908	CcSEcCtD
Bosutinib—SIK1—lymph node—uterine cancer	0.000217	0.000653	CbGeAlD
Bosutinib—IRAK4—lymph node—uterine cancer	0.000217	0.000653	CbGeAlD
Bosutinib—Dysgeusia—Epirubicin—uterine cancer	0.000216	0.000901	CcSEcCtD
Bosutinib—ABL1—uterus—uterine cancer	0.000216	0.000648	CbGeAlD
Bosutinib—EPHA4—lymph node—uterine cancer	0.000215	0.000647	CbGeAlD
Bosutinib—Back pain—Epirubicin—uterine cancer	0.000213	0.00089	CcSEcCtD
Bosutinib—ERBB3—lymph node—uterine cancer	0.000213	0.00064	CbGeAlD
Bosutinib—MAP2K2—lymph node—uterine cancer	0.000213	0.000639	CbGeAlD
Bosutinib—ULK3—lymph node—uterine cancer	0.000213	0.000639	CbGeAlD
Bosutinib—Dizziness—Etoposide—uterine cancer	0.000212	0.000886	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—uterine cancer	0.000212	0.000884	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—uterine cancer	0.000211	0.000882	CcSEcCtD
Bosutinib—MAP3K2—lymph node—uterine cancer	0.000211	0.000634	CbGeAlD
Bosutinib—MAP3K7—lymph node—uterine cancer	0.000209	0.000628	CbGeAlD
Bosutinib—CSK—Daunorubicin—Epirubicin—uterine cancer	0.000207	0.0224	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—uterine cancer	0.000207	0.0224	CbGdCrCtD
Bosutinib—PTK2—lymph node—uterine cancer	0.000207	0.000621	CbGeAlD
Bosutinib—TBK1—lymph node—uterine cancer	0.000207	0.000621	CbGeAlD
Bosutinib—CHEK2—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	0.000206	0.0224	CbGdCrCtD
Bosutinib—Ill-defined disorder—Epirubicin—uterine cancer	0.000205	0.000854	CcSEcCtD
Bosutinib—Vomiting—Etoposide—uterine cancer	0.000204	0.000852	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—uterine cancer	0.000204	0.000852	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—uterine cancer	0.000204	0.000851	CcSEcCtD
Bosutinib—IRAK1—lymph node—uterine cancer	0.000203	0.000609	CbGeAlD
Bosutinib—Rash—Etoposide—uterine cancer	0.000202	0.000845	CcSEcCtD
Bosutinib—Dermatitis—Etoposide—uterine cancer	0.000202	0.000844	CcSEcCtD
Bosutinib—Headache—Etoposide—uterine cancer	0.000201	0.00084	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—uterine cancer	0.0002	0.000834	CcSEcCtD
Bosutinib—RPS6KB1—lymph node—uterine cancer	0.000199	0.000597	CbGeAlD
Bosutinib—Malaise—Epirubicin—uterine cancer	0.000199	0.00083	CcSEcCtD
Bosutinib—PDGFRB—female gonad—uterine cancer	0.000198	0.000595	CbGeAlD
Bosutinib—FGR—lymph node—uterine cancer	0.000198	0.000594	CbGeAlD
Bosutinib—LCK—lymph node—uterine cancer	0.000198	0.000594	CbGeAlD
Bosutinib—Leukopenia—Epirubicin—uterine cancer	0.000197	0.000824	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—uterine cancer	0.000197	0.000824	CcSEcCtD
Bosutinib—PDGFRB—vagina—uterine cancer	0.000197	0.000592	CbGeAlD
Bosutinib—AXL—lymph node—uterine cancer	0.000197	0.000591	CbGeAlD
Bosutinib—ABL1—female reproductive system—uterine cancer	0.000194	0.000583	CbGeAlD
Bosutinib—Cough—Epirubicin—uterine cancer	0.000192	0.000803	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—uterine cancer	0.000192	0.0208	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—uterine cancer	0.000192	0.0208	CbGdCrCtD
Bosutinib—Nausea—Etoposide—uterine cancer	0.000191	0.000796	CcSEcCtD
Bosutinib—SLK—lymph node—uterine cancer	0.000189	0.000569	CbGeAlD
Bosutinib—Ill-defined disorder—Doxorubicin—uterine cancer	0.000189	0.00079	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—uterine cancer	0.000188	0.000787	CcSEcCtD
Bosutinib—EPHB4—lymph node—uterine cancer	0.000188	0.000565	CbGeAlD
Bosutinib—Chest pain—Epirubicin—uterine cancer	0.000188	0.000784	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—uterine cancer	0.000188	0.000784	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—uterine cancer	0.000188	0.000784	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000186	0.000778	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—uterine cancer	0.000185	0.000774	CcSEcCtD
Bosutinib—EPHA2—lymph node—uterine cancer	0.000185	0.000554	CbGeAlD
Bosutinib—FYN—lymph node—uterine cancer	0.000184	0.000553	CbGeAlD
Bosutinib—Malaise—Doxorubicin—uterine cancer	0.000184	0.000768	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—uterine cancer	0.000183	0.000762	CcSEcCtD
Bosutinib—MAP3K3—lymph node—uterine cancer	0.00018	0.000541	CbGeAlD
Bosutinib—MAP4K5—lymph node—uterine cancer	0.00018	0.000541	CbGeAlD
Bosutinib—Oedema—Epirubicin—uterine cancer	0.00018	0.000751	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—uterine cancer	0.00018	0.000751	CcSEcCtD
Bosutinib—CHEK2—Testosterone Propionate—Progesterone—uterine cancer	0.00018	0.0195	CbGdCrCtD
Bosutinib—Infection—Epirubicin—uterine cancer	0.000179	0.000746	CcSEcCtD
Bosutinib—Cough—Doxorubicin—uterine cancer	0.000178	0.000743	CcSEcCtD
Bosutinib—ABL1—female gonad—uterine cancer	0.000177	0.00053	CbGeAlD
Bosutinib—Nervous system disorder—Epirubicin—uterine cancer	0.000176	0.000737	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—uterine cancer	0.000176	0.000735	CcSEcCtD
Bosutinib—ABL1—vagina—uterine cancer	0.000175	0.000527	CbGeAlD
Bosutinib—Skin disorder—Epirubicin—uterine cancer	0.000175	0.00073	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—uterine cancer	0.000174	0.000725	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—uterine cancer	0.000174	0.000725	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—uterine cancer	0.000174	0.000725	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000172	0.00072	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—uterine cancer	0.000172	0.000716	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—uterine cancer	0.000166	0.000695	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—uterine cancer	0.000166	0.000695	CcSEcCtD
Bosutinib—YES1—lymph node—uterine cancer	0.000166	0.0005	CbGeAlD
Bosutinib—Infection—Doxorubicin—uterine cancer	0.000165	0.000691	CcSEcCtD
Bosutinib—STK10—lymph node—uterine cancer	0.000165	0.000495	CbGeAlD
Bosutinib—TAOK3—lymph node—uterine cancer	0.000164	0.000493	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000164	0.000684	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—uterine cancer	0.000163	0.000682	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—uterine cancer	0.000163	0.000681	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—uterine cancer	0.000162	0.000675	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—uterine cancer	0.00016	0.00067	CcSEcCtD
Bosutinib—SRC—lymph node—uterine cancer	0.00016	0.000481	CbGeAlD
Bosutinib—Decreased appetite—Epirubicin—uterine cancer	0.000156	0.000653	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000155	0.000649	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—uterine cancer	0.000155	0.000648	CcSEcCtD
Bosutinib—Pain—Epirubicin—uterine cancer	0.000154	0.000642	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000152	0.000633	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—uterine cancer	0.000152	0.0164	CbGdCrCtD
Bosutinib—CHEK2—Danazol—Progesterone—uterine cancer	0.00015	0.0162	CbGdCrCtD
Bosutinib—Dyspnoea—Doxorubicin—uterine cancer	0.000148	0.00062	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—uterine cancer	0.000148	0.000619	CcSEcCtD
Bosutinib—MAP2K5—lymph node—uterine cancer	0.000147	0.000442	CbGeAlD
Bosutinib—Gastrointestinal pain—Epirubicin—uterine cancer	0.000147	0.000614	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—uterine cancer	0.000145	0.000604	CcSEcCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—uterine cancer	0.000145	0.0157	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—uterine cancer	0.000145	0.0157	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—uterine cancer	0.000145	0.0157	CbGdCrCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000144	0.0006	CcSEcCtD
Bosutinib—CSF1R—lymph node—uterine cancer	0.000144	0.000431	CbGeAlD
Bosutinib—Fatigue—Doxorubicin—uterine cancer	0.000144	0.000599	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—uterine cancer	0.000143	0.000597	CcSEcCtD
Bosutinib—Pain—Doxorubicin—uterine cancer	0.000142	0.000594	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—uterine cancer	0.000142	0.000594	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—uterine cancer	0.000142	0.000594	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—uterine cancer	0.00014	0.0152	CbGdCrCtD
Bosutinib—Feeling abnormal—Doxorubicin—uterine cancer	0.000137	0.000573	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000136	0.000568	CcSEcCtD
Bosutinib—CHEK2—Norethindrone—Progesterone—uterine cancer	0.000135	0.0146	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—uterine cancer	0.000134	0.0145	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—uterine cancer	0.000134	0.0145	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—uterine cancer	0.000134	0.0145	CbGdCrCtD
Bosutinib—Urticaria—Doxorubicin—uterine cancer	0.000132	0.000552	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—uterine cancer	0.000132	0.000549	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—uterine cancer	0.000132	0.000549	CcSEcCtD
Bosutinib—Asthenia—Epirubicin—uterine cancer	0.000129	0.000539	CcSEcCtD
Bosutinib—PDGFRB—lymph node—uterine cancer	0.000127	0.000383	CbGeAlD
Bosutinib—Pruritus—Epirubicin—uterine cancer	0.000127	0.000531	CcSEcCtD
Bosutinib—Diarrhoea—Epirubicin—uterine cancer	0.000123	0.000514	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—uterine cancer	0.000119	0.000499	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—uterine cancer	0.000119	0.000497	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—uterine cancer	0.000118	0.000492	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—uterine cancer	0.000114	0.000478	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—uterine cancer	0.000114	0.000476	CcSEcCtD
Bosutinib—ABL1—lymph node—uterine cancer	0.000113	0.000341	CbGeAlD
Bosutinib—Rash—Epirubicin—uterine cancer	0.000113	0.000474	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—uterine cancer	0.000113	0.000473	CcSEcCtD
Bosutinib—Headache—Epirubicin—uterine cancer	0.000113	0.000471	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—uterine cancer	0.00011	0.00046	CcSEcCtD
Bosutinib—CHEK2—Levonorgestrel—Progesterone—uterine cancer	0.000107	0.0116	CbGdCrCtD
Bosutinib—Nausea—Epirubicin—uterine cancer	0.000107	0.000446	CcSEcCtD
Bosutinib—CYP3A4—renal system—uterine cancer	0.000106	0.00032	CbGeAlD
Bosutinib—Vomiting—Doxorubicin—uterine cancer	0.000106	0.000442	CcSEcCtD
Bosutinib—Rash—Doxorubicin—uterine cancer	0.000105	0.000438	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—uterine cancer	0.000105	0.000438	CcSEcCtD
Bosutinib—Headache—Doxorubicin—uterine cancer	0.000104	0.000435	CcSEcCtD
Bosutinib—ABCB1—myometrium—uterine cancer	0.000103	0.000311	CbGeAlD
Bosutinib—Nausea—Doxorubicin—uterine cancer	9.89e-05	0.000413	CcSEcCtD
Bosutinib—CYP3A4—female reproductive system—uterine cancer	8.52e-05	0.000256	CbGeAlD
Bosutinib—ABCB1—epithelium—uterine cancer	8.12e-05	0.000244	CbGeAlD
Bosutinib—ABCB1—uterine cervix—uterine cancer	8.05e-05	0.000242	CbGeAlD
Bosutinib—ABCB1—decidua—uterine cancer	7.67e-05	0.000231	CbGeAlD
Bosutinib—ABCB1—renal system—uterine cancer	7.53e-05	0.000226	CbGeAlD
Bosutinib—ABCB1—endometrium—uterine cancer	7.28e-05	0.000219	CbGeAlD
Bosutinib—ABCB1—mammalian vulva—uterine cancer	7.04e-05	0.000212	CbGeAlD
Bosutinib—ABCB1—uterus—uterine cancer	6.71e-05	0.000202	CbGeAlD
Bosutinib—ABCB1—female reproductive system—uterine cancer	6.03e-05	0.000181	CbGeAlD
Bosutinib—ABCB1—female gonad—uterine cancer	5.49e-05	0.000165	CbGeAlD
Bosutinib—ABCB1—vagina—uterine cancer	5.46e-05	0.000164	CbGeAlD
Bosutinib—ABCB1—lymph node—uterine cancer	3.53e-05	0.000106	CbGeAlD
Bosutinib—MAP2K1—Immune System—KRAS—uterine cancer	2.68e-06	6.45e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—PIK3CA—uterine cancer	2.68e-06	6.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ESR1—uterine cancer	2.67e-06	6.43e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—EP300—uterine cancer	2.67e-06	6.42e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HRAS—uterine cancer	2.67e-06	6.41e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—AKT1—uterine cancer	2.66e-06	6.41e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ERBB2—uterine cancer	2.66e-06	6.4e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCL2—uterine cancer	2.66e-06	6.39e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—CTNNB1—uterine cancer	2.65e-06	6.39e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VEGFA—uterine cancer	2.65e-06	6.37e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ERBB2—uterine cancer	2.65e-06	6.37e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KRAS—uterine cancer	2.65e-06	6.37e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EP300—uterine cancer	2.63e-06	6.33e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—PIK3CA—uterine cancer	2.63e-06	6.33e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CDKN1B—uterine cancer	2.62e-06	6.3e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CXCL8—uterine cancer	2.62e-06	6.3e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NRAS—uterine cancer	2.62e-06	6.29e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—AKT1—uterine cancer	2.61e-06	6.29e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HRAS—uterine cancer	2.61e-06	6.27e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—NRAS—uterine cancer	2.61e-06	6.27e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CDKN1B—uterine cancer	2.59e-06	6.24e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—RRM2—uterine cancer	2.59e-06	6.24e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—uterine cancer	2.59e-06	6.23e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PTEN—uterine cancer	2.59e-06	6.22e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KRAS—uterine cancer	2.58e-06	6.21e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—PIK3CA—uterine cancer	2.58e-06	6.2e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—PIK3CA—uterine cancer	2.58e-06	6.2e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EP300—uterine cancer	2.57e-06	6.19e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HRAS—uterine cancer	2.57e-06	6.18e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—PIK3CA—uterine cancer	2.57e-06	6.18e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CXCL8—uterine cancer	2.56e-06	6.17e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—AKT1—uterine cancer	2.56e-06	6.16e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CDKN1B—uterine cancer	2.56e-06	6.15e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—KRAS—uterine cancer	2.55e-06	6.13e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CXCL8—uterine cancer	2.52e-06	6.07e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—DCN—uterine cancer	2.52e-06	6.05e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—PIK3CA—uterine cancer	2.52e-06	6.05e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CXCL8—uterine cancer	2.51e-06	6.04e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—PIK3CA—uterine cancer	2.5e-06	6.02e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CDKN1B—uterine cancer	2.5e-06	6.02e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—NRAS—uterine cancer	2.5e-06	6.01e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HRAS—uterine cancer	2.49e-06	6e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—uterine cancer	2.49e-06	6e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—uterine cancer	2.49e-06	6e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—uterine cancer	2.49e-06	6e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—KRAS—uterine cancer	2.49e-06	5.99e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—PIK3CA—uterine cancer	2.48e-06	5.98e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—PIK3CA—uterine cancer	2.48e-06	5.96e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CTNNB1—uterine cancer	2.48e-06	5.96e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HRAS—uterine cancer	2.48e-06	5.96e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KRAS—uterine cancer	2.48e-06	5.96e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EP300—uterine cancer	2.47e-06	5.94e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CDKN1B—uterine cancer	2.46e-06	5.93e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NRAS—uterine cancer	2.46e-06	5.93e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—PIK3CA—uterine cancer	2.46e-06	5.93e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—uterine cancer	2.46e-06	5.92e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—uterine cancer	2.46e-06	5.91e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CDKN1B—uterine cancer	2.45e-06	5.9e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CTNNB1—uterine cancer	2.45e-06	5.9e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HRAS—uterine cancer	2.44e-06	5.86e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PIK3CA—uterine cancer	2.43e-06	5.85e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CTNNB1—uterine cancer	2.42e-06	5.81e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PTEN—uterine cancer	2.41e-06	5.8e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—NRAS—uterine cancer	2.41e-06	5.79e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KRAS—uterine cancer	2.41e-06	5.79e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—uterine cancer	2.4e-06	5.78e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTEN—uterine cancer	2.39e-06	5.75e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—uterine cancer	2.38e-06	5.74e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—uterine cancer	2.38e-06	5.74e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—uterine cancer	2.38e-06	5.72e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—uterine cancer	2.37e-06	5.71e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PIK3CA—uterine cancer	2.37e-06	5.71e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.37e-06	5.7e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CTNNB1—uterine cancer	2.37e-06	5.69e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PTEN—uterine cancer	2.35e-06	5.66e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—uterine cancer	2.35e-06	5.66e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL2—uterine cancer	2.35e-06	5.66e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—PIK3CA—uterine cancer	2.34e-06	5.63e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—uterine cancer	2.33e-06	5.6e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CTNNB1—uterine cancer	2.33e-06	5.6e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—uterine cancer	2.33e-06	5.6e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—uterine cancer	2.32e-06	5.57e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CTNNB1—uterine cancer	2.32e-06	5.57e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—NRAS—uterine cancer	2.31e-06	5.55e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PTEN—uterine cancer	2.31e-06	5.55e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—uterine cancer	2.3e-06	5.54e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EP300—uterine cancer	2.3e-06	5.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB2—uterine cancer	2.3e-06	5.53e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—uterine cancer	2.3e-06	5.53e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—uterine cancer	2.29e-06	5.51e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PIK3CA—uterine cancer	2.29e-06	5.5e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—uterine cancer	2.28e-06	5.48e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EP300—uterine cancer	2.28e-06	5.48e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PIK3CA—uterine cancer	2.27e-06	5.47e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTEN—uterine cancer	2.27e-06	5.46e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—uterine cancer	2.27e-06	5.46e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTEN—uterine cancer	2.26e-06	5.43e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—uterine cancer	2.25e-06	5.42e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—uterine cancer	2.25e-06	5.41e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EP300—uterine cancer	2.25e-06	5.4e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—uterine cancer	2.24e-06	5.4e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.24e-06	5.39e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—uterine cancer	2.22e-06	5.33e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—uterine cancer	2.21e-06	5.32e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—uterine cancer	2.2e-06	5.3e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EP300—uterine cancer	2.2e-06	5.29e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—uterine cancer	2.19e-06	5.28e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—uterine cancer	2.19e-06	5.26e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—uterine cancer	2.18e-06	5.25e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—uterine cancer	2.18e-06	5.25e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—uterine cancer	2.18e-06	5.24e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—uterine cancer	2.17e-06	5.21e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EP300—uterine cancer	2.16e-06	5.21e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EP300—uterine cancer	2.15e-06	5.18e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—uterine cancer	2.15e-06	5.18e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—uterine cancer	2.15e-06	5.17e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—uterine cancer	2.15e-06	5.17e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—uterine cancer	2.14e-06	5.15e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—uterine cancer	2.14e-06	5.15e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—uterine cancer	2.13e-06	5.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1B—uterine cancer	2.13e-06	5.12e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—uterine cancer	2.13e-06	5.12e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—uterine cancer	2.13e-06	5.12e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—uterine cancer	2.12e-06	5.1e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—uterine cancer	2.12e-06	5.09e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—uterine cancer	2.11e-06	5.08e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—uterine cancer	2.11e-06	5.07e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—uterine cancer	2.11e-06	5.07e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—uterine cancer	2.1e-06	5.06e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—uterine cancer	2.1e-06	5.06e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—uterine cancer	2.1e-06	5.05e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—uterine cancer	2.1e-06	5.05e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—uterine cancer	2.08e-06	5.01e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—uterine cancer	2.07e-06	4.98e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—uterine cancer	2.07e-06	4.98e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—uterine cancer	2.06e-06	4.96e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—uterine cancer	2.06e-06	4.95e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—uterine cancer	2.05e-06	4.94e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1B—uterine cancer	2.05e-06	4.94e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—uterine cancer	2.05e-06	4.93e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—uterine cancer	2.05e-06	4.92e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—uterine cancer	2.05e-06	4.92e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—uterine cancer	2.04e-06	4.91e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—uterine cancer	2.03e-06	4.88e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—uterine cancer	2.02e-06	4.87e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—uterine cancer	2.02e-06	4.87e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—uterine cancer	2.02e-06	4.85e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—uterine cancer	2.01e-06	4.85e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—uterine cancer	2.01e-06	4.84e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—uterine cancer	2.01e-06	4.84e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—uterine cancer	2e-06	4.81e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—uterine cancer	1.99e-06	4.78e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—uterine cancer	1.99e-06	4.78e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—uterine cancer	1.98e-06	4.76e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—uterine cancer	1.98e-06	4.75e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—uterine cancer	1.96e-06	4.72e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTEN—uterine cancer	1.96e-06	4.72e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—uterine cancer	1.95e-06	4.69e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—uterine cancer	1.94e-06	4.66e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—uterine cancer	1.94e-06	4.66e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—uterine cancer	1.91e-06	4.6e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—uterine cancer	1.91e-06	4.6e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—uterine cancer	1.91e-06	4.59e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—uterine cancer	1.9e-06	4.58e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTEN—uterine cancer	1.89e-06	4.55e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—uterine cancer	1.88e-06	4.53e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EP300—uterine cancer	1.87e-06	4.5e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—uterine cancer	1.87e-06	4.49e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—uterine cancer	1.86e-06	4.48e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—uterine cancer	1.86e-06	4.47e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—uterine cancer	1.85e-06	4.46e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—uterine cancer	1.83e-06	4.41e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—uterine cancer	1.83e-06	4.4e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—uterine cancer	1.83e-06	4.39e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1B—uterine cancer	1.82e-06	4.37e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—uterine cancer	1.81e-06	4.35e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—uterine cancer	1.81e-06	4.35e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—uterine cancer	1.8e-06	4.34e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EP300—uterine cancer	1.8e-06	4.34e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—uterine cancer	1.78e-06	4.29e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—uterine cancer	1.77e-06	4.26e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—uterine cancer	1.77e-06	4.26e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—uterine cancer	1.76e-06	4.24e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—uterine cancer	1.75e-06	4.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—uterine cancer	1.75e-06	4.2e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—STK11—uterine cancer	1.74e-06	4.2e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.74e-06	4.2e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—uterine cancer	1.74e-06	4.19e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—uterine cancer	1.73e-06	4.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—uterine cancer	1.72e-06	4.13e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—uterine cancer	1.71e-06	4.11e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—uterine cancer	1.7e-06	4.1e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—uterine cancer	1.69e-06	4.07e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—uterine cancer	1.69e-06	4.06e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—uterine cancer	1.69e-06	4.06e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—uterine cancer	1.69e-06	4.05e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—uterine cancer	1.68e-06	4.05e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTEN—uterine cancer	1.67e-06	4.02e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—uterine cancer	1.66e-06	4e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—uterine cancer	1.65e-06	3.96e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—uterine cancer	1.63e-06	3.91e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—uterine cancer	1.61e-06	3.88e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—uterine cancer	1.61e-06	3.87e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—uterine cancer	1.6e-06	3.85e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EP300—uterine cancer	1.6e-06	3.84e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—uterine cancer	1.59e-06	3.83e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—uterine cancer	1.59e-06	3.83e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—uterine cancer	1.57e-06	3.79e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—uterine cancer	1.57e-06	3.79e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—uterine cancer	1.56e-06	3.75e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—uterine cancer	1.55e-06	3.74e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—uterine cancer	1.55e-06	3.73e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—uterine cancer	1.54e-06	3.71e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—uterine cancer	1.54e-06	3.7e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—uterine cancer	1.51e-06	3.64e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—uterine cancer	1.51e-06	3.62e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—uterine cancer	1.5e-06	3.62e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—uterine cancer	1.49e-06	3.59e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—uterine cancer	1.49e-06	3.59e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—uterine cancer	1.48e-06	3.56e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—uterine cancer	1.47e-06	3.54e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—uterine cancer	1.45e-06	3.49e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—uterine cancer	1.39e-06	3.35e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—uterine cancer	1.38e-06	3.33e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—uterine cancer	1.38e-06	3.31e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—uterine cancer	1.36e-06	3.26e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—uterine cancer	1.34e-06	3.22e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—uterine cancer	1.33e-06	3.21e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—uterine cancer	1.33e-06	3.2e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—uterine cancer	1.31e-06	3.15e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—uterine cancer	1.31e-06	3.15e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—uterine cancer	1.3e-06	3.13e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—uterine cancer	1.29e-06	3.1e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—uterine cancer	1.28e-06	3.09e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—uterine cancer	1.28e-06	3.08e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—uterine cancer	1.23e-06	2.97e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTEN—uterine cancer	1.18e-06	2.85e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—uterine cancer	1.18e-06	2.84e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—uterine cancer	1.14e-06	2.75e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—uterine cancer	1.13e-06	2.72e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—EP300—uterine cancer	1.13e-06	2.72e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—uterine cancer	1.09e-06	2.63e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—uterine cancer	1.09e-06	2.62e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—uterine cancer	9.64e-07	2.32e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—uterine cancer	8.35e-07	2.01e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTEN—uterine cancer	7.29e-07	1.75e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—EP300—uterine cancer	6.95e-07	1.67e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—uterine cancer	6.82e-07	1.64e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	5.14e-07	1.24e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—uterine cancer	4.2e-07	1.01e-06	CbGpPWpGaD
